Page last updated: 2024-12-05

4-chloro-alpha,alpha,alpha-trifluorotoluene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-chloro-alpha,alpha,alpha-trifluorotoluene: RN given refers to cpd with specified locants for chloride & trifluoromethyl moieties; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7394
CHEMBL ID1797001
SCHEMBL ID196588
MeSH IDM0113938

Synonyms (80)

Synonym
EN300-20053
toluene, p-chloro-.alpha.,.alpha.,.alpha.-trifluoro-
nsc-10309
1-chloro-4-(trifluoromethyl)benzene
p-chlorotrifluoromethylbenzene
nsc10309
benzene, 1-chloro-4-(trifluoromethyl)-
p-chlorobenzotrifluoride
p-chloro-.alpha.,.alpha.-trifluorotoluene
p-trifluoromethylphenyl chloride
4-chlorobenzotrifluoride
(p-chlorophenyl)trifluoromethane
4-chloro-.alpha.,.alpha.-trifluorotoluene
98-56-6
1-(trifluoromethyl)-4-chlorobenzene
p-(trifluoromethyl)chlorobenzene
NCGC00091724-01
p-chloro-a,a,a-trifluorotoluene
hsdb 4251
einecs 202-681-1
4-chloro-alpha,alpha,alpha-trifluorotoluene
alpha,alpha,alpha-trifluoro-4-chlorotoluene
nsc 10309
para-chloro-alpha,alpha,alpha-trifluorotoluene
brn 0510203
toluene, p-chloro-alpha,alpha,alpha-trifluoro-
ccris 720
p-chloro-alpha,alpha,alpha-trifluorotoluene
para-chlorobenzotrifluoride
para-chlorotrifluoromethylbenzene
inchi=1/c7h4clf3/c8-6-3-1-5(2-4-6)7(9,10)11/h1-4
4-chlorobenzotrifluoride, 98%
NCGC00091724-02
4-chloro-a,a,a-trifluorotoluene
AKOS005067495
NCGC00091724-03
CHEMBL1797001
4-trifluoromethylchlorobenzene
tox21_303261
dtxsid7024821 ,
NCGC00257114-01
dtxcid004821
cas-98-56-6
NCGC00258996-01
tox21_201445
4-(trifluoromethyl)chlorobenzene
pcbtf
ec 202-681-1
694yo34jhc ,
unii-694yo34jhc
FT-0618189
p-(trifluoromethyl) chlorobenzene
STL268887
n-(2,4-dimethylphenyl)-3-hydroxy-naphthalene-2-carboxamide
SCHEMBL196588
chloro-alpha,alpha,alpha-trifluorotoluene, 4-
chlorobenzotrifluoride, p-
(4-chlorophenyl)trifluoromethane
4-chloro-.alpha.,.alpha.,.alpha.-trifluorotoluene
p-chlorobenzotrifluoride [mi]
1-chloro-4-(trifluoromethyl)benzene [hsdb]
4-chloro-benzotrifluoride
4-chlorobenzo-trifluoride
4-chloro trifluoromethylbenzene
4-trifluoromethyl chlorobenzene
1-chloro-4-trifluoromethylbenzene
1-trifluoromethyl-4-chlorobenzene
parachlorobenzotrifluoride
chloro-4-(trifluoromethyl)benzene
p-chloro-.alpha.,.alpha.,.alpha.-trifluorotoluene
AM87507
W-100075
1219804-33-7
mfcd00000627
AC-10097
BCP24446
Q410670
4-chlorobenzotrifuoride
(p-chlorophenyl)trifluoromethane;4-chlorobenzyltrifluoride;
4-chloro-a,a,a-trifluorotoluene-d4

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" With both vehicles CTFT and alpha 2u-globulin were found to accumulate in the male rat kidney after 14 days of exposure and a dose-related toxic nephropathy was observed at dose of 50 mg/kg or higher."( Application of molecular encapsulation for toxicology studies: comparative toxicity of p-Chloro-alpha, alpha, alpha-trifluorotoluene in alpha-cyclodextrin vehicle versus corn oil vehicle in male and female Fischer 344 rats and B6C3F1 mice.
Carlton, T; Corniffe, G; Elwell, MR; Goehl, TJ; Jameson, CW; Leininger, JR; Thompson, MB; Yuan, J, 1992
)
0.28

Bioavailability

ExcerptReferenceRelevance
" Dose proportionality for CTFT was established up to 400 mg/kg and bioavailability was shown to be complete for both vehicles."( Application of molecular encapsulation for toxicology studies: toxicokinetics of p-chloro-alpha,alpha,alpha-trifluorotoluene in alpha-cyclodextrin or corn oil vehicles in male F344 rats.
Collins, BJ; Goehl, TJ; Jameson, CW; Judd, L; Purdie, W; Yuan, JM, 1991
)
0.28

Dosage Studied

ExcerptRelevanceReference
" The hepatocellular hypertrophy and cytoplasmic vacuolation of the adrenal cortex which appeared in dosed male and female rats were also found to be independent of vehicle."( Application of molecular encapsulation for toxicology studies: comparative toxicity of p-Chloro-alpha, alpha, alpha-trifluorotoluene in alpha-cyclodextrin vehicle versus corn oil vehicle in male and female Fischer 344 rats and B6C3F1 mice.
Carlton, T; Corniffe, G; Elwell, MR; Goehl, TJ; Jameson, CW; Leininger, JR; Thompson, MB; Yuan, J, 1992
)
0.28
" Serial blood samples were taken from a cannulated jugular vein for up to 52 hr after dosing and the CTFT concentrations in whole blood were determined by gas chromatography."( Application of molecular encapsulation for toxicology studies: toxicokinetics of p-chloro-alpha,alpha,alpha-trifluorotoluene in alpha-cyclodextrin or corn oil vehicles in male F344 rats.
Collins, BJ; Goehl, TJ; Jameson, CW; Judd, L; Purdie, W; Yuan, JM, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.13060.006038.004119,952.5996AID1159521
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency31.62280.000214.376460.0339AID588532
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.13060.000229.305416,493.5996AID743079
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00140.023723.228263.5986AID588543
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency30.63790.001723.839378.1014AID743083
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency7.94220.010039.53711,122.0200AID588545; AID588547
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID603950In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID603951In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID603952In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's2 (20.00)18.2507
2000's1 (10.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.72 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]